BMS-986253 + Immunotherapy for Advanced Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called BMS-986253 along with other cancer treatments, Nivolumab and Ipilimumab, in patients with advanced cancers to see if it can improve their effectiveness.
Will I have to stop taking my current medications?
The trial does not specify if you must stop all current medications, but you cannot take certain immunosuppressive medications or corticosteroids above a certain dose within 14 days of starting the study. Also, if you are on cytotoxic agents, you need to wait at least 4 weeks after your last dose before starting the trial.
What data supports the effectiveness of the drug BMS-986253 + Immunotherapy for Advanced Cancer?
Research shows that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) has been effective in treating advanced non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, with better survival rates compared to chemotherapy. This suggests that similar combinations, like BMS-986253 with immunotherapy, might also be effective for advanced cancers.12345
What is the safety profile of BMS-986253 and related immunotherapies?
Immunotherapies like ipilimumab and nivolumab can cause immune-related side effects, which may include diarrhea, liver inflammation, lung issues, kidney problems, and heart issues. While most side effects are mild and manageable, some can be serious and require hospital visits or stopping the treatment. It's important for patients to be monitored closely and treated promptly if side effects occur.678910
What makes the drug BMS-986253 + Immunotherapy unique for advanced cancer?
This treatment combines BMS-986253, an anti-IL-8 drug, with the immunotherapy drugs nivolumab and ipilimumab, which are known to enhance the body's immune response against cancer. This combination is unique because it targets multiple pathways to potentially improve treatment effectiveness compared to using these drugs individually.2341112
Research Team
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
This trial is for adults with advanced solid tumors, who are physically capable of daily activity or light work. They must have a tumor that can be measured and one that's reachable for biopsy. People taking high-dose steroids, recent cytotoxic agents, those with HIV/AIDS, or active autoimmune diseases cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BMS-986253
- Ipilimumab
- Nivolumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania